Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.

Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.

Item
http://www.wikidata.org/entity/Q37142453
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysisA self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly.Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone ClubStrontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis.Cutaneous side effects of antiosteoporosis treatments.Use of the self-controlled case series method in drug safety assessmentInhaled tiotropium bromide and risk of strokeLooking back: editors' pick of 2008.Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.Mechanical loading, an important factor in the evaluation of ion release from bone augmentation materials
P2860

Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.

Item
http://www.wikidata.org/entity/Q37142453
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Post-marketing assessment of t ...... ion of adverse drug reactions.
@en
Post-marketing assessment of t ...... ion of adverse drug reactions.
@nl
type
label
Post-marketing assessment of t ...... ion of adverse drug reactions.
@en
Post-marketing assessment of t ...... ion of adverse drug reactions.
@nl
prefLabel
Post-marketing assessment of t ...... ion of adverse drug reactions.
@en
Post-marketing assessment of t ...... ion of adverse drug reactions.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Post-marketing assessment of t ...... ion of adverse drug reactions.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2125.2008.03273.X
P407
P433
P478
P50
P577
P5875
P698
P932